<DOC>
	<DOCNO>NCT02206087</DOCNO>
	<brief_summary>Normal subject receive unfractionated heparin follow single dose PER977 dose escalation cohort . Ten subject enrol Cohort 4 receive single dose PER977 follow one-week washout receive unfractionated heparin follow single dose PER977 . The study provide insight dos may require reverse anticoagulation induce heparin . PER977 administration follow heparin sodium injection acceptable safety tolerability profile impact pro-coagulant biomarkers .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics , Pharmacodynamic Effects PER977 Following Heparin</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Adults age 18 65 year , inclusive 2 . Laboratory value clinically significant abnormality judge Investigator . 3 . No clinically significant finding 12lead electrocardiogram 4 . Body mass index ( BMI ) 18 ≤ 27 kg/m2 , inclusive 5 . Male subject agree use appropriate contraception . 6 . Female subject may surgically sterile postmenopausal , childbearing potential , must negative serum pregnancy test prior enrollment , must agree use two form acceptable contraception duration study minimum one complete menstrual cycle 28 day follow discharge study . 7 . Subjects must understand agree comply requirement study must willing sign inform consent form indicate voluntary consent participate study prior initiation screen study related activity . 1 . History current evidence clinically significant disease Current evidence liver function test renal function test ( serum creatinine ) great upper limit normal . The presence Gilbert 's Syndrome acceptable . Current evidence QTcF &gt; normal ( 450±10 msec male 470±10 msec female ) . 2 . History unexplained syncope 3 . Hypersensitivity unfractionated heparin , thrombocytopenia positive vitro test antiplatelet antibody presence unfractionated heparin , hypersensitivity heparin porcine product contraindication unfractionated heparin 4 . History major bleeding , trauma , surgical procedure type , vaginal delivery within six month prior screen 5 . History peptic ulcer , gastrointestinal bleeding bleeding hemorrhoid within six month prior screen 6 . History minor bleeding episode epistaxis , gingival bleeding within 1 month prior screen 7 . Personal family history clot disorder abnormality , excessive bleeding , thrombovascular disease hematologic disorder involve platelet clot abnormality condition require treatment transfusion , personal history heparininduced thrombocytopenia 8 . Females history dysfunctional uterine bleed undergone hysterectomy , include history menorrhagia , metrorrhagia polymenorrhea 9 . Pregnant breastfeed 10 . Males history hormone therapy within 3 month prior screen 11 . Administration blood product anticoagulant within 3 month prior study entry nonsteroidal antiinflammatory drug cyclooxygenase inhibitor within 2 week prior dose . 12 . Taking type medication 14 consecutive day within 4 week prior study entry 13 . Positive serologic test HIV , hepatitis C antibody , hepatitis B surface antigen 14 . Donation blood blood product within 56 day prior screen 15 . History randomization prior study PER977 16 . Randomization study investigational compound device within 30 day prior sign inform consent 17 . Active drug alcohol dependence within prior 12 month condition , opinion Investigator , would interfere adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PER977</keyword>
	<keyword>heparin</keyword>
	<keyword>anticoagulation reversal</keyword>
	<keyword>whole blood clotting time</keyword>
</DOC>